Company profile
Climb Bio, Inc.
NASDAQ:CLYMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Budoprutug | phase2 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07090655 | — | completed | 2025-08-11 | 2026-04-07 | Climb Bio, Inc. | A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers |
| NCT07248865 | phase1 | recruiting | 2025-12-02 | 2026-07-01 | Climb Bio, Inc. | A Phase 1 Study of CLYM116 in Normal Healthy Volunteers |
| NCT07011043 | phase1 | recruiting | 2025-07-10 | 2027-04-01 | Climb Bio, Inc. | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
| NCT07043946 | phase1_2 | recruiting | 2025-06-30 | 2027-08-01 | Climb Bio, Inc. | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) |
| NCT07564596 | phase1_2 | recruiting | 2026-06-30 | 2027-09-01 | Climb Bio, Inc. | A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
FDA applications (0)
No records yet.